Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag safety and efficacy in adults with early ITP
NCT05046327Phase 3Withdrawn
- Sponsor
- Sobi
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of avatrombopag in immune thrombocytopenia (ITP), sponsored by Sobi. Planned start Oct 2021; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05046327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046327.